


Genomics is changing the way we diagnose, understand, and treat cancer. SearchLight DNA™ uses the power of genomics to identify clinically important cancer mutations in our pets.

SearchLight DNA™ now makes it possible to identify clinically relevant mutations in dog cancers.



What does SearchLight DNA™ do?

By finding mutations in the DNA of your pet's cancer cells, Vidium's SearchLight DNA™ can guide your veterinary team in understanding a cancer's origin, its behavior, and the optimal approach to its treatment.

What does the report reveal?



The Most Relevant Alterations in the Tumor's DNA

Using next-generation sequencing of 120 cancer-associated genes selected based on the latest scientific literature and databases, SearchLight DNA™ provides the clinical team and pet family with confidence that if a mutation with clinical value is present, we've found it. These mutations can inform diagnosis, prognosis, and treatment planning.



Easily Understandable Summaries of What We Know About These Mutations

Vidium scientists have assembled the latest published data in human and veterinary studies to provide the most up-to-date knowledge database possible. We deliver that information to the healthcare team in a detailed-but-digestible and well-referenced format.



Targeted Therapies

Using data from veterinary and human oncology, SearchLight DNA™ provides information on therapies that may be indicated by mutations in a pet's tumor. It also provides a summary of the scientific evidence associated with those indications.



Clinical Trials

Leveraging the AVMA's Clinical Trials Database alongside supplemental curation of trials at academic centers and through industry sponsors, Vidium provides the healthcare team with up-to-date information on additional options for pets with cancer.

A Closer Look at SearchLight DNA™



SearchLight DNA™ is a “pan-cancer” precision diagnostic, prognostic, and therapeutic indicator, using a targeted NGS (Next-Generation Sequencing) 482kB gene panel that identifies point mutations, copy number mutations, and internal tandem duplications in 120 known cancer genes, as well as the chemo-sensitivity gene *MDR1*. It is appropriate for FFPE, FNA, or fresh frozen tumor samples. SearchLight DNA™ is the most informative canine cancer genetic test available: It incorporates all high-quality diagnostic, prognostic, and predictive biomarkers known from canine and human cancer studies into a proprietary knowledge database that has been curated from more than 300 canine-specific publications. It also brings inference from human publications and databases. We provide you with 2 detailed, annotated reports: one designed for the clinician, the other designed for passing on to the pet parent if you choose.

How Does SearchLight DNA™ Work?

From a sample of the pet's tumor, we use custom next-generation sequencing technology and our proprietary genomic knowledge database built on clinical and scientific publications to generate a report for the veterinarian. The report clearly describes all the mutations found in the dog's tumor, it summarizes what's currently known about the association of those mutations with cancer diagnosis, prognosis, and treatment, and it identifies relevant clinical trials.



Cancer Patient

The pet with suspected cancer visits the veterinarian.



Veterinary Team

The veterinary team performs a biopsy to collect a sample of the tumor. The sample is sent to Vidium or is sent to a pathologist and then sent to Vidium.



Vidium Animal Health

Vidium performs tumor DNA sequencing and analysis with SearchLight DNA™, annotating the tumor mutations with biomarker data from its knowledge database.



Reports

Vidium provides a detailed report to the veterinary team with information about the tumor's mutations and their associations with diagnosis, prognosis, and treatment.

Leveraging the best science available to help you and your patients.

Vidium is dedicated to unravelling the genetic components of common and complex diseases, including cancer. As a result, the practice of medicine targeting these conditions can be more rational, more precise, and more personal. Our focus is on shifting paradigms in cancer treatment to enable cures for cancer and other serious diseases in pets through programs at the intersection of personalized medicine and comparative genomics.

Vidium Animal Health

For more information, please visit www.vidiumah.com.

Vidium HQ

445 N 5th Street
4th Floor
Phoenix, AZ 85004

Customer Support

Call 1-833-794-0318
Email VidiumInfo@tgen.org

